Related Experiment Video

Updated: Aug 4, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Effects of protein kinase C inhibitors on thromboxane production by thrombin-stimulated platelets

G P Samokhin1, M R Jirousek, D K Ways

  • 1Section of Allergy, Asthma and Immunology, Department of Medicine, East Carolina University, Greenville, NC 27858-4354, USA.

European Journal of Pharmacology
|January 5, 2000
PubMed

Insights

Protein kinase C delta plays a role in thromboxane production in human platelets. Other protein kinase C isoforms, alpha and beta, do not significantly impact this process.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Hematology

Background:

  • Platelet activation and aggregation are critical hemostatic processes.
  • Thromboxane A2 is a potent mediator of platelet aggregation and vasoconstriction.
  • Protein kinase C (PKC) is a family of enzymes involved in various cellular signaling pathways.

Purpose of the Study:

  • To investigate the role of protein kinase C (PKC) in regulating thromboxane production in human platelets.
  • To elucidate the specific PKC isoforms involved in thromboxane synthesis.

Main Methods:

  • Human platelets were stimulated with thrombin, Thrombin Quick I, or a protease-activated receptor-1 (PAR-1) agonist peptide (TRAP).
  • The effects of four different PKC inhibitors, including isoform-selective agents, on thromboxane production were assessed.
  • Thromboxane levels were quantified using established biochemical assays.

Main Results:

  • The bisindolylmaleimide derivative GF 109203X increased thromboxane production, suggesting it may inhibit a negative feedback mechanism.
  • The PKC delta-selective inhibitor rottlerin decreased thromboxane production, indicating a role for PKC delta.
  • PKC beta-selective inhibitor (379196) and Gö 6976 did not significantly alter thromboxane production.

Conclusions:

  • Protein kinase C delta is likely involved in the regulation of thromboxane synthesis in human platelets.
  • Classical PKC isoforms alpha and beta do not appear to play a significant role in this pathway.
  • Complex regulatory mechanisms, potentially involving negative feedback, influence thromboxane production.

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...